US FDA seeks comments on draft guidance on user fee waivers, reductions and refunds
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has published for stakeholder comment draft guidance on how sponsors of drugs and biologicals can request user fee waivers, refunds or reductions1,2.
You may also be interested in...
US Orphan Fee Waiver Requests Must Include Much More Extensive Documentation
In update of 2011 draft guidance, FDA gives more detail on documentation needed for orphan sponsors to receive a program fee waiver; Guidance also suggests the agency is no longer working with SBA to make small business determinations.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.